Market research
TTNP Titan Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 1.38
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8883146065
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 1.38
About
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TTNP discussion.
5 years, 4 months ago
Titan Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 13.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Titan Pharmaceuticals, Inc's total revenue sank by 13.1% to $1M since the same quarter in the previous year.
Its net income has increased by 21.7% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 21.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Titan Pharmaceuticals, Inc gets an overall score of 2/5.